Curiteva Adds Steve Cichy as Strategic Advisor and Erik Erbe, PhD, as Vice President of Clinical and Research

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Curiteva, Inc. announced today the addition of Steve Cichy as a Strategic Advisor to the rapidly growing technology company headquartered in Huntsville, Alabama.

Cichy is an industry veteran who most recently led the Titan Spine sales organization for 13 years through a successful acquisition by Medtronic in 2019. “I recognized Curiteva as a true platform company with world-class manufacturing and operations. I appreciate the company’s passion for innovation highlighted by their acquisition of Fossil Labs last year. I’m confident, based on my recent experience, that this is the next generation of novel interbody technology and I wanted to be a part of the team when it hits the market later this year.”

The company also announced the hiring of Erik Erbe, Ph.D., as Vice President, Clinical and Research. Dr. Erbe is a 30-year industry veteran with over 50 issued U.S. patents and specific expertise in chemical processing of ceramic biomaterials, innovative biologics, and clinical research. “What Todd Reith and the team at Curiteva are doing with 3D printing will alter the course of bone healing and open the door to significant advancement within orthopedics, trauma, and neurosurgery,” stated Dr. Erbe.

Curiteva released limited details regarding the technology but has described it as Fused Filament Fabrication 3D printing of PEEK to deliver an implant with controlled interconnected macroporosity throughout the entire implant rather than only the endplates. In addition, the technology boasts advanced hydrophilicity and increased bioactive surface area for osseointegration that will revolutionize interbody fusion in spine as well as adjacent markets in healthcare and medical device.

“Steve and Erik are talented, experienced leaders in our industry. We are honored they are joining Curiteva to drive our commercial success and guide the launch of our novel interbody platform,” stated CEO Mike English.

Curiteva announced the close of an oversubscribed Series A raise at $20.5 million in September of 2020 and plans to deploy the capital to expand infrastructure and drive the successful commercialization of its novel R&D platform in 2021.




Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.